148 related articles for article (PubMed ID: 12686811)
1. Patterns of care for the treatment of bladder cancer.
Snyder C; Harlan L; Knopf K; Potosky A; Kaplan R
J Urol; 2003 May; 169(5):1697-701. PubMed ID: 12686811
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program.
Konety BR; Joslyn SA
J Urol; 2003 Nov; 170(5):1765-71. PubMed ID: 14532772
[TBL] [Abstract][Full Text] [Related]
4. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study.
Prout GR; Wesley MN; Yancik R; Ries LA; Havlik RJ; Edwards BK
Cancer; 2005 Oct; 104(8):1638-47. PubMed ID: 16130136
[TBL] [Abstract][Full Text] [Related]
5. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
6. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population.
Schrag D; Mitra N; Xu F; Rabbani F; Bach PB; Herr H; Begg CB
Urology; 2005 Jun; 65(6):1118-25. PubMed ID: 15922428
[TBL] [Abstract][Full Text] [Related]
7. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden.
Jahnson S; Damm O; Hellsten S; Holmäng S; Liedberg F; Ljungberg B; Malmström PU; Månsson W; Strömberg F; Wijkstöm H
Scand J Urol Nephrol; 2009; 43(4):271-6. PubMed ID: 19424934
[TBL] [Abstract][Full Text] [Related]
9. Understanding bladder cancer death: tumor biology versus physician practice.
Morris DS; Weizer AZ; Ye Z; Dunn RL; Montie JE; Hollenbeck BK
Cancer; 2009 Mar; 115(5):1011-20. PubMed ID: 19152434
[TBL] [Abstract][Full Text] [Related]
10. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
11. Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program.
Konety BR; Dhawan V; Allareddy V; Joslyn SA
J Urol; 2005 Jun; 173(6):2085-9. PubMed ID: 15879848
[TBL] [Abstract][Full Text] [Related]
12. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
Kulkarni GS; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Alibhai SM
PLoS Med; 2007 Sep; 4(9):e284. PubMed ID: 17896857
[TBL] [Abstract][Full Text] [Related]
14. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
[TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
17. Bladder and upper tract urothelial cancer.
Konety BR; Joyce GF; Wise M
J Urol; 2007 May; 177(5):1636-45. PubMed ID: 17437776
[TBL] [Abstract][Full Text] [Related]
18. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
19. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
20. Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States.
Le A; Berger D; Lau M; El-Serag HB
Ann Surg Oncol; 2007 Sep; 14(9):2519-27. PubMed ID: 17610016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
